SLC22A3 and prostate neoplasm: Higher methylation and lower expression of SLC22A1 and SLC22A3 was previously observed in hepatocellular carcinoma and prostate tumor compared with matched normal samples [13, 14] supporting that higher methylation in metformin transporter genes could be associated with disease.